10 drugs expected to lead US sales in 2026

 Statista, a global data company that publishes insights for 170 industries, projects four cancer therapies will be among the top 10 best-selling pharmaceutical products in the U.S. this year. 

The company projects Merck’s cancer drug Keytruda will earn $12.7 billion in U.S. revenue in 2026 — nearly twice that of the second top-selling medication, according to data shared March 9 with Becker’s. 

Here are the medications Statista projects will be the 10 best-selling U.S. pharmaceutical products in 2026: 

1. Keytruda — $12.7 billion

Manufacturer: Merck

FDA-approved for about a dozen cancers, including non-small cell lung cancer and melanoma

2. Biktarvy — $8.2 billion

Manufacturer: Gilead Sciences

FDA-approved as an HIV-1 treatment

3. Eliquis — $7.8 billion

Manufacturer: BMS

FDA-approved as a blood thinner medicine to reduce blood clotting

4. Imbruvica — $6.7 billion

Manufacturer: AbbVie 

FDA-approved for several blood cancers and chronic graft-versus-host disease

5. Dupixent — $6.4 billion

Manufacturer: Sanofi

FDA-approved for nine chronic inflammatory conditions, including chronic obstructive pulmonary disease

6. Opdivo — $6.1 billion

Manufacturer: BMS

FDA-approved for more than a dozen cancers, including melanoma and renal cell carcinoma

7. Ozempic — $6 billion

Manufacturer: Novo Nordisk

FDA-approved for Type 2 diabetes, cardiovascular disease and kidney disease

8. Trikafta — $6 billion

Manufacturer: Vertex

FDA-approved for cystic fibrosis

9. Ocrevus — $5.9 billion

Manufacturer: Roche

FDA-approved for multiple sclerosis

10. Ibrance — $5.9 billion

Manufacturer: Pfizer

FDA-approved for breast cancer

https://www.beckershospitalreview.com/pharmacy/10-drugs-expected-to-lead-us-sales-in-2026/